Centiva Capital’s Cellebrite CLBT Stock Holding History

Centiva Capital’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,500	Closed	-$27.7K	–	2114
2024 Q1	$27.7K	Buy	+2,500	New	+$25.5K	﹤0.01%	1668

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Centiva Capital's CLBT Position: Q2 2026 in Review

Centiva Capital sold out of Cellebrite (CLBT) in Q2 2026, closing a stake of 25,058 shares — an estimated $345K sold.

Centiva Capital first reported a position in CLBT in Q4 2023 and held it in 6 quarters. The position peaked at $1.94M in Q2 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

Centiva Capital reported no remaining Cellebrite position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 25,058 Cellebrite shares in Q2 2026, an estimated $345K.
Centiva Capital first reported a position in Cellebrite in Q4 2023 and held it in 6 quarters.
Centiva Capital's Cellebrite position peaked at $1.94M in Q2 2024.
201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.